Sort
46,585 grants matching “heart failure”
Tobacco Products and Atherosclerotic Disease
$744,350Sanjay Srivastava · University Of Louisville · R01 · FY2013 · HL
Tobacco Products and Atherosclerotic Disease
$744,350Sanjay Srivastava · University Of Louisville · R01 · FY2017 · HL
Integrated Coagulation Sensing to Predict Hemorrhage and Guide Transfusions
$744,296Seemantini K Nadkarni · Massachusetts General Hospital · R01 · FY2025 · HL
Enhancement of an Artificial Lung for Ambulatory Respiratory Support
$744,283Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2023 · HL
Enhancement of an Artificial Lung for Ambulatory Respiratory Support
$744,283Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2022 · HL
Development and Pre-Clinical Trial Qualification of a Pediatric Pump-Lung System for Children
$744,248Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2021 · HL
Targeting cardiovascular events to improve patient outcomes after sepsis
$744,234Allan J. Walkey · Boston University Medical Campus · R01 · FY2018 · HL
Immune-compatible, unfixed, xenogeneic extracellular matrix for heart valve prostheses
$744,229Maelene L Wong · Vivita Technologies, Inc. · R44 · FY2023 · HL
Understanding mechanisms of Fontan failure and key predictors for patient outcome
$744,227Ajit P Yoganathan · Georgia Institute Of Technology · R01 · FY2012 · HL
CTRIP Ex-vivo perfusion and ventilation of lungs to assess transplant suitability
$744,201Thomas M. Egan · Univ Of North Carolina Chapel Hill · RC2 · FY2010 · HL
MDM2-HIF signaling in pathological ventricular remodeling
$744,195Jason Becker · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · HL
MDM2-HIF signaling in pathological ventricular remodeling
$744,195Jason Becker · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · HL
Risk Stratification in MADIT II Type Patients
$744,156Wojciech Zareba · University Of Rochester · R01 · FY2006 · HL
Development of Mirror-Image Natural Products as Antiarrhythmic Therapeutics
$744,145Jeffrey Nicholas Johnston · Vanderbilt University · R01 · FY2025 · HL
Immune reconstitution following autologous and allogeneic stem cell transplant
$744,123Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Completely biological tissue-engineered pulmonic valve grown in vitro from human cells for pediatric patients
$744,121Robert T Tranquillo · University Of Minnesota · R01 · FY2019 · HL
Characterization and Genetics of KI toxicity in iPSC-derived cardiomyocytes
$744,112Ulrich Broeckel · Medical College Of Wisconsin · R01 · FY2020 · HL
Bioengineering of Transplantable Humanized Lungs from iPS Cells
$744,106Darrell N. Kotton · Boston University Medical Campus · R01 · FY2014 · HL
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
$744,066Richard W Gross · Washington University · R01 · FY2015 · HL
Mechanisms of Maladaptation in Heart Failure
$744,055Howard A Rockman · Duke University · R01 · FY2021 · HL
Neurocognition and Greater Maintenance of Sinus Rhythm in AF (NOGGIN AF)
$744,011Joseph P Mathew · Duke University · R01 · FY2024 · AG
Benefits of ICU admission for patients with acute respiratory failure or sepsis: A mixed-methods study across 26 hospitals
$743,873Scott D Halpern · University Of Pennsylvania · R01 · FY2020 · HL
Elucidating hereditary transthyretin-mediated heart failure risk using machine learning, polygenic risk and recall by genotype approaches in African ancestry individuals
$743,821Ron Do · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · HL
Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy
$743,820Wojciech Zareba · University Of Rochester · R01 · FY2021 · HL
Catheter Ablation versus Antiarrythmic Drug Therapy for Atrial Fibrilllation Tria
$743,814Douglas L Packer · Mayo Clinic Rochester · U01 · FY2012 · HL